Rapid clearance of extensive juvenile pityriasis rubra pilaris with ixekizumab
Pediatric Dermatology · 2024
DOI: 10.1111/pde.15700 ↗Kurz gefasst
Fallbericht in der Zeitschrift Pediatric Dermatology, 2024. Verfasst von Eun Jae Kim und 2 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Pityriasis Rubra Pilaris, Antibodies, Monoclonal, Humanized, Dermatologic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 8 Literaturangaben.
Abstract (Originalsprache)
Juvenile pityriasis rubra pilaris is a rare inflammatory skin disorder currently without any FDA‐approved treatments, and lesions can be refractory to conventional treatment with topical corticosteroids, methotrexate, and oral retinoids. We herein present a case of a 6‐year‐old boy who attained clearance of extensive juvenile pityriasis rubra pilaris within 2 weeks of starting ixekizumab therapy. Therapeutic effect has been durable at 6 months, and patient continues on therapy without adverse effects. Our case highlights a new, rapidly effective treatment option for pediatric patients with this rare condition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Harvard Medical School, Boston, Massachusetts, USA.
- Dermatology Program, Boston Children's Hospital, Boston, Massachusetts, USA.
ORCID-Profile: Eun Jae Kim
Zitieren
APA
Kim, E. J., Corey, K., & Damji, Y. (2024). Rapid clearance of extensive juvenile pityriasis rubra pilaris with ixekizumab. Pediatric Dermatology. https://doi.org/10.1111/pde.15700
Vancouver
Kim EJ, Corey K, Damji Y. Rapid clearance of extensive juvenile pityriasis rubra pilaris with ixekizumab. Pediatric Dermatology. 2024. doi:10.1111/pde.15700
BibTeX
@article{Kim2024,
author = {Kim, Eun Jae and Corey, Kristen and Damji, Yasin},
title = {Rapid clearance of extensive juvenile pityriasis rubra pilaris with ixekizumab},
journal = {Pediatric Dermatology},
year = {2024},
doi = {10.1111/pde.15700}
}
EUVIMED